Navigation Links
Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
Date:3/12/2009

LAS VEGAS, March 12 /PRNewswire-FirstCall/ -- Gamma Pharmaceuticals Inc. (OTC Bulletin Board: GMPM) announces the receipt of purchase orders for its Jugular(R) brand Energy Products from Folsom Distributing in St. Louis, Missouri. Folsom Distributing services the QuikTrip Convenience Store outlets in St. Louis and the surrounding area. QuikTrip requested Folsom Distributing to contract directly with Gamma on its behalf. Gamma has developed a series of programs to promote its branded products. Gamma estimates that its brand promotion program developed for the St. Louis Market should result in revenue of up to $850,000 in the territory over the next 12 months. Gamma's CEO Peter Cunningham commented, "Our QuikTrip relationship will significantly boost Gamma's Jugular(R) branded products in this important market. We feel QuikTrip, the premier convenience store chain in St. Louis, will drive our market share performance and overall brand profile."

Gamma Pharmaceuticals Inc. is a marketing and product formulation company. Gamma has created, registered and branded innovative product lines that include Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize its patent pending "Gel Delivery Technology(R)"; offering consumers one of the most innovative gel product lines in the market today. Gamma uses its patent pending gel delivery technology to formulate one of the industry's only full suites of gel based products. Gamma benefits from a clear consumer preference for gel product forms; offering consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma targets consumers in the fast growing Greater China and U.S. wellness and healthcare markets. Primary channels are retail pharmacies, supermarkets, club stores and other big box outlets. Secondary channels include internet and direct selling. Gamma uses third party distributors and sells directly to retail outlets.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.


'/>"/>
SOURCE Gamma Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study Determines Breast-Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms
2. Breast-Specific Gamma Imaging (BSGI) Changes Patient Care Management
3. Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
4. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
5. Gamma Labs to Boost Testosterone At World Series of Poker In Las Vegas
6. Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer
7. San Antonio Community Hospital Commissions Leksell Gamma Knife(R) Perfexion(TM) To Serve Over 3 Million Californians
8. Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging
9. STERIS Isomedix Services Offers Gamma Engineering Run Program
10. Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
11. Dual-head gamma camera increases ability to detect breast tumors not seen on mammography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... Tx (PRWEB) , ... February 17, 2017 , ... ... revenue cycle management services, announced today that Karen Pilley has been promoted to ... is critical in today’s shifting healthcare paradigm – a shift that demands the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer ... Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part of ... anatomic and molecular pathology workflow solution, as well as its new precision medicine ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017  Noble ... coverage on ESSA Pharma Inc. (Nasdaq: EPIX ... Biotechnology Research, Kumar Raja , PhD. ... treatments for castration resistant prostate cancer (CRPC). Its lead ... selectively blocks the amino-terminal domain of the androgen receptor, ...
Breaking Medicine Technology: